Targeting of $\alpha_v\beta_3$-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles

Aim: Receptor-specific small molecules and nanoparticles are widely used in molecular imaging of tumors. Although some studies have described the relative strengths and weaknesses of the two approaches, reports of a direct comparison and analysis of the two strategies are lacking. Herein, we compared the tumor-targeting characteristics of a small near-infrared fluorescent compound (cypate–peptide conjugate) and relatively large perfluorocarbon-based nanoparticles (250 nm diameter) for imaging $\alpha_v\beta_3$-integrin receptor expression in tumors. Materials & methods: Near-infrared fluorescent small molecules and nanoparticles were administered to living mice bearing subcutaneous or intradermal syngeneic tumors and imaged with whole-body and high-resolution optical imaging systems. Results: The nanoparticles, designed for vascular constraint, remained within the tumor vasculature while the small integrin-avid ligands diffused into the tissue to target integrin expression on tumor and endothelial cells. Targeted small-molecule and nanoparticle contrast agents preferentially accumulated in tumor tissue with tumor-to-muscle ratios of 8 and 7, respectively, compared with 3 for nontargeted nanoparticles. Conclusion: Fluorescent small molecular probes demonstrate greater overall early tumor contrast and rapid visualization of tumors, but the vascular-constrained nanoparticles are more selective for detecting cancer-induced angiogenesis. A combination of both imaging agents provides a strategy to image and quantify integrin expression in tumor tissue and tumor-induced neovascular systems.

KEYWORDS: $\alpha_v\beta_3$-integrin angiogenesis cancer emulsion fluorescence near-infrared optical imaging peptide perfluorocarbon

Until recently, most imaging agents used in humans relied on small organic or inorganic molecules with typical hydrodynamic diameters of less than a few nanometers. However, the emergence of nanotechnology has expanded the horizon of medical imaging to include nanoparticles as contrast agents. Both small molecules and nanoparticles have distinct advantages in molecular imaging. Nanoparticles offer a high surface-to-volume ratio that accommodates functionalization with multiple homing ligands for increased binding avidity or with contrast molecules for amplified imaging signals [1]. Moreover, nanoparticles can be engineered for vascular constraint, which eliminates confounding imaging signals from nontarget extravascular tissues. By contrast, small molecules targeted to diagnostic proteins can extravasate and bind a variety of cell types expressing the target biomolecules. In addition, rapid internalization of small molecules in cells can take advantage of receptor recycling patterns of a given target to improve overall tissue contrast relative to the surroundings.

Many studies have demonstrated the successful use of both small molecules and nanoparticles in receptor-mediated selective delivery of imaging agents and drugs to disease tissues. For example, proliferating tumors are known to generate new blood vessels, a process known as angiogenesis. Angiogenesis is an important microanatomical feature of tumor development characterized by the unique intraluminal expression of the $\alpha_v\beta_3$-integrin receptor on the surface of proliferating endothelial cells [2,3]. Therefore, contrast agents consisting of small molecules and nanoparticles targeted to $\alpha_v\beta_3$-integrin receptor have been used to image tumor neovasculature by nuclear, optical, ultrasound and MRI methods [4–6]. For example, the ability of peptides possessing the arginine–glycine–aspartic acid (RGD) sequence to bind $\alpha_v\beta_3$-integrin receptors with high affinity allows their use to develop integrin-selective imaging agents.

Near-infrared (NIR) fluorescent dyes, such as cypate, are preferred for optical imaging in living animals owing to the relative transparency of biological tissue to light in the 700–900 nm wavelength range [7]. The limited penetration of light in deep tissue confines its applications to shallow tissues and organs. However, this imaging method is exquisitely suitable for use in small-animal models of human diseases,
especially for preclinical studies. Previous studies demonstrate that conjugation of cypate to cyclo(RGDfK) peptide produced an integrin-avid molecular probe cypate–cRGDFK (Figure 1) with selective tumor uptake in tumor-bearing mice [8].

Similarly, a variety of αβ3-integrin-targeted nanoparticles have been developed [1,5]. We chose to examine αβ3-integrin-targeted per-fluorocarbon-based nanoparticles (PFC-NPs) with an average diameter of 250 nm as a flexible multifunctional platform for molecular imaging and drug delivery [9]. In contrast to other commonly reported nanoparticle-based imaging agents, these nanoparticles are sufficiently large to remain within the vascular lumen, providing an opportunity to evaluate only endothelial αβ3 expression [10]. In addition, a clear translational path is available since the particles are formulated with biocompatible materials [9]. Incorporation of homing ligands and imaging molecules into the encapsulating lipid surfactant monolayer afforded high sensitivity for noninvasive detection and characterization of cancer-induced angiogenesis in multiple animal studies [11–17].

While both integrin-specific small molecules and nanoparticles have been used in molecular imaging of tumors, the relative strengths and weaknesses of the two approaches have never been directly examined. In this study, we prepared cypate–cRGDFK peptide and NIR fluorescent αβ3-integrin-targeted PFC-NPs (cypate–PFC-tNPs) (Figure 1) and evaluated these in mouse cancer models. We chose to compare these specific contrast agents to evaluate the different utilities of highly diffusive, small-molecular-weight contrast agents and large nanoparticles that remain within the blood vessels. The cypate–cRGDFK was small enough to encounter αβ3-integrin expression by tumor, stromal and endothelial cells, while the large nanoparticles were directed to intravascular αβ3-integrin expression alone. The magnitude, as well as the spatial and temporal differences in tumor-related contrast generated by the highly penetrant fluorescent small molecule versus the vascular-constrained nanoparticle system, were delineated to assess the clinical opportunities and challenges of each technology.

**Materials & methods**

**NIR fluorescent imaging agents**

Cypate and cypate–cRGDFK (Figure 1) were synthesized as previously reported [7,8,18]. A hydrophobic derivative of cypate, cypate–C18 (Figure 1) was synthesized by conjugating cypate with 1-octadecylamine to increase hydrophobicity for inclusion in the hydrophobic core of the PFC-NPs. Cypate (30 mg, 1 eq.) was dissolved in 5 ml of dimethyl formamide in a round-bottom flask, and 1-octadecylamine (2.1 eq.) HBTU (4 eq.) and diisopropylethylamine (2 eq.) were added. After stirring at room temperature for 1 h, dimethyl formamide was evaporated under a vacuum and the residue was redissolved in ethyl acetate, washed with saturated NaHCO3/water and brine, dried over MgSO4 and concentrated under a vacuum. The product was purified by high performance liquid chromatography (water/acetonitrile in 0.1% trifluoroacetic acid) and lyophilized to give 7 mg of the desired compound as green powder. Yield: 12%, [M+] = 1129. The fluorescent compound was used in nanoparticle formulation.

**PFC-NP formulation**

Near-infrared fluorescent cypate–PFC-NPs (Figure 1) were prepared by using similar methods to those described previously [15,19]. The emulsions comprised 20% (v/v) perfluorooctylbromide, 2.0% (w/v) of a surfactant comixture, and 1.7% (w/v) glycerin in distilled, deionized water. Targeted PFC-NPs (Figure 1) were prepared by incorporating a peptidomimetic quinolone αβ3-integrin antagonist-targeting ligand developed by Bristol-Myers Squibb Medical Imaging (NY, USA) [16]. The surfactant comixture of peptidomimetic nanoparticles included 98 mol% lecithin (Avanti Polar Lipids, Inc., AL, USA), 0.1 mol% of peptidomimetic quinolone conjugated to PEG2000-phosphatidylethanolamine (Kereos, Inc., MO, USA), and 1.9 mol% phosphatidylethanolamine (Avanti Polar Lipids, Inc., AL, USA). Nontargeted nanoparticles excluded the quinolone ligand from the surfactant, which was replaced with equimolar phosphatidylethanolamine, a neutral phospholipid (Figure 1). The surfactant components were combined with the perfluorooctylbromide, water and glycerin, the pH was adjusted to 7.5, and the mixture was emulsified with an M110 microfluidizer (Microfluidics, Newton, MA, USA) at 20,000 psi for 4 min. For NIR fluorescent nanoparticles, the dye was substituted for lecithin on an equimolar basis at 0.1 and 0.3% for approximately 400 and 1200 molecules per nanoparticle, respectively. Nominal particle sizes and polydispersity (typically 250 nm with a polydispersity of 0.18) were measured with a dynamic light-scattering technique (Brookhaven Instrument Corp., NY, USA).
Spectroscopy

Each sample (0.1 ml) was added to 0.9 ml of phosphate buffered saline in a cuvette and analyzed by absorption and fluorescence spectroscopy. The absorption spectra of the samples were recorded on a Beckman–Coulter DU-640 spectrophotometer (CA, USA). Fluorescence spectra were recorded on a Fluorolog III fluorometer (Horiba Jobin Yvon Inc., NJ, USA) with 720 nm excitation and 735–950 nm emission scan. Samples were measured in standard 1 cm quartz cells. Quantum yield was measured relative to indocyanine green in dimethyl sulfoxide (DMSO) [20]. All measurements were performed at room temperature. Fluorescence lifetime was measured using the time-correlated single-photon counting technique with a NanoLed™ 773 nm excitation source, impulse...
repetition rate of 1 MHz at 90° to the detector (Hamamatsu Photonics, Shizuoka, Japan). The detector was set to 820 nm with a 20-nm bandpass. The instrument response function was obtained using Rayleigh scatter of Ludox-40 (Sigma Aldrich, MO, USA) at a dispersion of 0.03% in Millipore-Q (ultrapure) water in a quartz cuvette at 773-nm emission. DAS6 v.6.1 decay analysis software (Horiba) was used for lifetime calculations. The fit was judged by χ² values and Durbin–Watson parameters, and visual observations of fitted line, residuals and autocorrelation function. The lifetime was recorded on a 50-ns scale and a total of 8200 channels were used with time calibration 6.87 × 10⁻⁸ ns/channel.

Time-resolved emission spectroscopy (TRES) was conducted using a NanoLed 773 nm excitation source and emissions from 775 to 900 nm. Time-gated traces were derived using a TRES software package implemented in fluorescence decay analysis software DAS6 (Horiba).

Stability testing of the NIR dye in the lipid surfactant monolayer was performed by measuring fluorescent lifetime of the PFC-NPs in the presence of 0.1% bovine serum albumin in phosphate buffered saline (1 ml). The thermal stability of the nanoparticles was investigated by heating the cuvette to 90°C using a Peltier-type heating accessory.

### Breast cancer models

All animal studies were performed in compliance with the Washington University School of Medicine Animal Studies Committee requirements for the humane care and use of laboratory animals in research. Luciferase-transfected 4T1 mouse mammary carcinoma cells (4T1luc) were cultured in Dulbecco’s Modified Eagle Medium. Mice were anesthetized by intraperitoneal injection of ketamine and xylazine cocktail for anesthesia, mice (n = 3) were anesthetized with isoflurane gas (2% v/v) and placed supine on the imaging platform of the NIR imaging system with the MousePod accessory (Odyssey, Li-Cor Biosciences, NE, USA). The imaging surface of mouse ears were coated with glycerin to improve contrast and autocorrelation function. The lifetime was recorded on a 50-ns scale and a total of 8200 channels were used with time calibration 6.87 × 10⁻⁸ ns/channel.

After a preinjection scan of the ears, either 0.10 ml of the nanoparticle solution (4 × 10¹⁳ particles/ml) or 0.02 ml (20 µM in 20% DMSO/water) cypate-cRGDFK was administered to the mouse by intravenous injection via the lateral tail vein. Mouse ears were imaged at different time points: before, immediately after, 4 and 24 h after injection. Injections and imaging were repeated on days 8 and 15 after tumor implantation. The fluorescence intensity within the blood vessels was compared with that of the nonvascular tissue to determine relative contrast.

Regions of interest were selected for the tumor region of the ear. Injected dose was estimated by measuring the fluorescence intensity from blood vessel ROIs in the postinjection image for each ear. ROIs were hand-drawn for tumors and the mean signal intensity measured. The remaining pixels were selected as a second ROI and background intensity was determined. Tumor-specific intensity was determined by subtracting background intensity from tumor intensity. These determined intensities were then normalized by injected dose as determined above.

### Whole-body imaging & biodistribution

The biodistribution of imaging agents in male nude mice with subcutaneous 4T1luc tumors was assessed by whole-body planar fluorescence reflectance imaging. Images were acquired after intravenous administration of 100 µl of 20 µM cypate-cRGDFK (in 20% DMSO/water) or 150 µl of the nanoparticle solution. NIR fluorescence (755 ± 35 nm excitation and 830 nm wide-angle emission filters, 60 s acquisition time), were acquired at 1, 4 and 24 h after injection using the Kodak IS4000MM multimodal imaging system (Carestream Health). White
light and digital x-ray images were acquired for anatomical reference. After the last imaging time point, mice were sacrificed and organ tissues were harvested and placed on a clear tray for fluorescence imaging. ROIs were selected using the automatic ROI selection function in the software by thresholding of the white-light image and transfer of ROIs to the fluorescence image.

- **Statistical analysis**

  Intradermal tumor growth rates were compared by nonlinear regression to assess the biological effects of contrast agents on tumor growth. Growth rates were compared by evaluating differences in exponential growth rate (k) values between groups. For ID and subcutaneous tumor imaging, mean fluorescence intensities for ROIs were compared between groups using Student’s t-test with α = 0.05. Statistical analyses were performed using Graphpad Prism 5.0.

**Results**

- **NIR fluorescent dye & homing ligands**

  The NIR fluorescent dye cypate was used as the fluorescent antenna for optical imaging. This dye was shown to have similar spectral properties and biodistribution profiles in small animals as indocyanine green, a NIR fluorescent dye approved for human use [21]. Upon conjugation to a cyclic RGD peptide, the resultant molecular probe (Figure 1) was shown to have high binding affinity to the αβ3 integrin receptor [8]. For nanoparticle formulation, we derivatized cypate with long alkyl chains to create a highly hydrophobic dye, cypate–C18 (Figure 1), suitable for encapsulation in the hydrophobic core of PFC-NPs. Stable nanoparticles were generated successfully (see later). We used the αβ3 integrin antagonist [16] developed by Bristol-Myers Squibb Medical Imaging for this study. The quinolone nonpeptide ligand did not perturb the stability of the nanoparticles. This ligand was initially reported and characterized as the 111In-DOTA conjugate RP748 and cyan 5.5 homolog TA145 [22]. It had high specificity for αβ3 integrin and a 15-fold preference for the Mn2+ activated receptor (IC50: 21 nM) [23]. The IC50 values for αβ3, αβ1, and GP IbIIa proteins were determined to be more than 10 μM [16].

- **Spectral analysis of fluorescent PFC-NPs**

  We determined the spectral properties of the cypate–C18, cypate–cRGDFK and the cypate–PFC-tNP. The absorption and emission properties of cypate–C18 and cypate–cRGDFK were essentially unchanged relative to nonconjugated cypate. Determination of the spectral properties of the PFC-NPs was more difficult because scattering dominated the absorption and emission spectra of the nanoparticles incorporating 0.1 and 0.3% NIR dye (Figure 2). To minimize the effect of scattering, we subtracted the absorption spectral profile of control-targeted PFC-NPs (non-fluorescent) from that of the cypate–PFC-NPs. The resulting spectra clearly show the presence of a NIR dye in solution (Figure 2), with strong absorption peaks detected at 680 and 797 nm, demonstrating stable incorporation of the dye in the hydrophobic layer. A fluorescence peak at approximately 815 nm was obscured by light scattering (not shown here), but became more apparent using TRES spectroscopy. The spectrum of the nanoparticle at 5 ns after excitation is shown in Figure 2B. Stability of the fluorescence intensity after adding albumin to the emulsion suggests that the dye was well retained in the nanoparticle surfactant. The NIR cypate–PFC-tNPs demonstrated high thermal stability for up to 15 min at 90°C, without a change in the absorption and emission spectra. Additional treatment of the preheated and cooled nanoparticles with albumin revealed no shift in emission, further indicating the stable retention of the cypate dye in the nanoparticle surfactant.

  The tabulated optical properties of cypate, cypate–C18, cypate–cRGDFK and cypate–PFC, including absorption maxima (λa), emission maxima (λem), molar absorptivity (ε), quantum yield (ϕ), and fluorescence lifetime (τ) are given in Table 1. The choice of solvents for this study was dictated by solubility and stability factors. Cypate and cypate–C18 form nonemissive aggregates in aqueous solutions, while cypate–cRGDFK is stable in 20% DMSO/water owing to the large hydrophilic peptide. Cypate–PFC liposomes were stable in water and unstable in less polar solvents.

- **High-resolution in vivo imaging**

  The ID tumor growth rate varied, with bioluminescence detected as early as 3 days after implantation. Imaging agents had no significant effect on the growth of tumor xenografts as determined by bioluminescence measurements (p = 0.94). The nanoparticles showed strong fluorescence in vitro and in vivo above 800 nm with a high signal-to-background ratio of 4.5 ± 0.8.
In vivo fluorescence from ear vasculature was high relative to surrounding tissues immediately after injection of the nanoparticles (Figure 3a), with vascular contrast sustained for up to 24 h. Fluorescence intensity in the blood vessels, after administration of the small molecular probes, was relatively short-lived, reflecting the rapid systemic clearance and extravasation into tissues. The relative plasma clearance and extravasation kinetics of the small-molecule and nanoparticle contrast agents produced the differences in the observed vascular contrast. The PFC-NPs possessed a significantly longer circulation half-life as well as a reduced rate of extravasation owing to larger size and biocompatible surface components, promoting the longer time for blood vessel visibility (Figure 3a). Metabolism of the agents, particularly degradation of the nanoparticles, could also have affected the in vivo distribution and imaging contrast.

Selectivity of tumor uptake was quantified by ROI analysis, comparing the measured fluorescence intensity for the tumor to that of the surrounding ear tissue. Tumor and normal vasculature were detected by high-resolution imaging of intradermal tumors in mouse ears (Figure 3a), while whole-body biodistribution of the NIR fluorescent contrast agents was assessed by planar fluorescence reflectance imaging in vivo (Figure 3B) and in ex vivo tissue sections (Figure 3C). The relative fluorescence intensity in the tumor region was much greater (p < 0.05) for the cypate–PFC-tNPs than for the small molecules, with Figure 4 showing 20–40% greater accumulation in the intradermal tumor area relative to the cypate–cRGDFK. The pharmacokinetic profile of fluorescence after nanoparticle administration matches that of other stable nanoparticles [10,24,25], indicating little or no loss of fluorescent contrast agent from nanoparticles in circulation.

Table 1. Spectroscopic properties of cypate-based fluorescent probes.

<table>
<thead>
<tr>
<th>Entry</th>
<th>( \lambda_{abs} ) (nm)</th>
<th>( \lambda_{em} ) (nm)</th>
<th>( \varepsilon \times 10^{-3} \text{ M}^{-1} \text{ cm}^{-1} )</th>
<th>( \phi )</th>
<th>( \tau ) (ns)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cypate(^{1})</td>
<td>790</td>
<td>817</td>
<td>224</td>
<td>0.12</td>
<td>0.97</td>
</tr>
<tr>
<td>Cypate–C18(^{2})</td>
<td>790</td>
<td>815</td>
<td>242</td>
<td>0.09</td>
<td>0.83</td>
</tr>
<tr>
<td>Cypate–cRGDFK(^{3})</td>
<td>790</td>
<td>804</td>
<td>n/d</td>
<td>0.036</td>
<td>0.24</td>
</tr>
<tr>
<td>Cypate–PFC-tNP(^{1})</td>
<td>797</td>
<td>813(^{4})</td>
<td>n/d(^{4})</td>
<td>n/d</td>
<td>n/d</td>
</tr>
</tbody>
</table>

\(^{1}\)Dimethyl sulfoxide.
\(^{2}\)20% dimethyl sulfoxide/water.
\(^{3}\)Water.
\(^{4}\)Measured via time-resolved emission spectroscopy spectroscopy.
\(^{4}\)Not determined owing to small sample size.

\( \lambda_{abs} \): Absorption maximum; \( \lambda_{em} \): Emission maximum; \( \varepsilon \): Molar absorptivity; \( \phi \): Quantum yield; \( \tau \): Fluorescence lifetime; n/d: Not determined; PFC-tNP: \( \alpha_\beta \)-integrin-targeted perfluorocarbon-based nanoparticle.
Angiogenesis was not detectable with the cypate–PFC-tNP at 3 days postimplantation of the tumor cells. However, tumor contrast was obvious at 7 days, suggesting that new proliferating blood vessels had sprouted and luminally expressed the αβ3-integrin, to which the cypate–PFC-tNP bound. The NIR contrast persisted in the tumor tissues for more than 24 h and still showed contrast 3 days after injection. Consistent with prior reports [12–14,17], non-targeted cypate–PFC-NPs were also entrapped within the disarrayed tumor neovasculature, but with much less signal intensity than the targeted cypate–PFC-tNP. The nonspecific uptake of

![Figure 3](https://www.futuremedicine.com)

**Figure 3. In vivo optical imaging with targeted fluorescent molecular probes.** (A) In vivo imaging of mouse ears with intradermal tumor region (circled) 9 days after implantation. Images were acquired by the raster-scanning method at 21 μm per pixel, providing high resolution of tumor area. The cypate–PFC-tNPs’ long plasma residence time and delayed extravasation relative to cypate–cRGDFK vasculature was demonstrated by visibility of blood vessels for more than 4 h after injection. (B) Whole-body near-infrared fluorescence images of mice bearing subcutaneous 4T1/luc tumor 24 h after injection of αβ3-targeted cypate–cRGDFK (left) or near-infrared fluorescent cypate–PFC-tNPs (right). (C) Fluorescence biodistribution imaging of ex vivo tissues 24 h after fluorescent probe injection. PFC-tNP: αβ3-targeted perfluorocarbon-based nanoparticle.
transferred passively to the outer leaflet of the target cell membrane and then through an ATP-dependent mechanism, the phospholipid-related entities can be translocated to the inner bilayer leaflet, providing contiguous transport throughout the inner cell membranes without endosomal sequestration [14]. The in vivo effectiveness of this mechanism of drug delivery has been repeatedly demonstrated in preclinical models of cancer, cardiovascular disease and arthritis [9,15,16,19,29]. The data presented here support this mechanism and illustrate how hydrophobic drugs, modeled by the NIR cypate dye in this study, may be carried systemically to tumor neovascular sites via αβ-integrin-targeted nanoparticles, delivered locally into the targeted endothelial cells along the growth front, and eventually dispersed further into the tumor parenchyma over time. Moreover, the significant enhancement in dye accumulation appreciated with integrin-specific versus the nontargeted nanoagents emphasized the benefit of active targeting of nanomedicines over simple passive accumulation.

The fluorescence contrast in the intradermal tumor area was higher for both types of nanoparticles, cypate–PFC-tNPs and cypate–PFC-NPs, than that of the small molecular probe at all times. This difference in contrast can be attributed to the higher permeability of the small molecules and greater distribution in the tumor and normal extravascular tissues relative to the nanoparticles. The small molecular probe attained peak tumor-to-normal contrast at 4 h postinjection, with similar contrast observed at 24 h. Unlike the nanoparticles, fluorescence from the small molecular probe was barely detectable 3 days after injection.

### Whole-body imaging & ex vivo biodistribution of imaging agents

Whole-body imaging of mice showed that the fluorescent small molecular probe cypate–cRGDFK and nanoparticles cypate–PFC-tNPs provided sufficient contrast for noninvasive tumor detection in vivo (Figure 3B). The imaging agents distributed throughout the body and accumulated highly in the liver region. Fluorescence from the small molecular probe was also detected in the kidneys. Tumor contrast was high for all the imaging agents at 24 h postinjection. In vivo tumor contrast was 1.32 ± 0.13 for cypate–cRGDFK and 1.57 ± 0.15 for targeted nanoparticles.

The relative biodistribution of the contrast agents was measured by ex vivo fluorescence imaging. The fluorescent nanoparticles showed...
Targeting of $\alpha_\beta_3$-integrins expressed on tumor tissue & neovasculature

high accumulation in the spleen and liver (Figure 3C), while the small molecular probe concentrated in the liver and kidneys (not shown). Uptake in the spleen is expected for the relatively large nanoparticulates [14,24]. High tumor accumulation occurred for both cypate–cRGD and cypate–PFC-tNPs and with tumor-to-muscle ratios of 8.1 and 6.9, respectively, compared with 3.0 for nontargeted cypate–PFC-NPs (Figure 5). Other reports corroborate this finding for long-circulating biocompatible nanoparticles [13,14] and the potential effect of this undesirable uptake should be considered in the design and evaluation of targeted agents.

Discussion
Molecular imaging with optical contrast agents holds many advantages in preclinical imaging and it has made significant inroads to clinical applications [30]. Owing to its high detection sensitivity, optical imaging is ideally suited for imaging molecular processes. For example, the $\alpha_\beta_3$-integrin receptor is highly expressed by proliferative cells, such as white blood cells, immature endothelial cells and many types of cancer cells [3,4]. Therefore, small molecular contrast agents based on the $\alpha_\beta_3$-integrin-avid RGD peptide motif have been extensively studied in preclinical models and some of these agents are under investigation for tumor detection in humans [3]. The conventional dogma for targeting $\alpha_\beta_3$-integrin in tumor imaging with small molecular probes is to improve the tumor-to-normal tissue contrast. A major challenge in targeting tumor-expressed $\alpha_\beta_3$-integrin is its ubiquitous expression on cells of the immune system, cancer and nascent endothelial cells. In such cases where the molecular target is expressed by a variety of tissue types, contrast agents that are constrained to the vasculature are better suited to differentiate luminal targets [5,31].

In this study, we used two different tumor models – intradermal and subcutaneous – to explore the effectiveness of generating contrast by using small molecular probes and nanoparticles. The intradermal tumor model provided a thin and well-vascularized small tumor tissue for optical imaging of tumors in the early growth phase. The high vascularization as early as 3 days postimplantation is useful for gauging the tumor perfusion. In this model, the extent of angiogenesis relative to tumor size appears highest at 7 days postimplantation.

Our results demonstrate that vascular-constrained nanoparticles are effective for detecting tumor-induced angiogenesis, while small molecular probes can identify the tumor tissue by extravasating and binding to the target tumor. This difference in the distribution of targeted imaging agents is clearly demonstrated in the intradermal tumor model. Extravasation of the small molecular probe reduced the tumor contrast at early time points owing to the high signal from surrounding normal tissues. On the contrary, the targeted nanoparticles provided higher contrast than the more diffusible small molecular probe. The high and prolonged uptake of the nanoparticles in the small tumors is likely owing to the high density of nascent blood vessels in this tumor model.

The small molecular probe and nanoparticles had different contrast effects on the subcutaneous tumor model. Tumors implanted subcutaneously are generally characterized by a poorly vascularized interior, with angiogenesis occurring primarily in the periphery [16]. This feature reflects the lower imaging contrast in tumor generated by the nanoparticle contrast than that of the small molecular probe. Unlike nanoparticles, the small molecular probe is capable of diffusing rapidly into the entire tumor tissue, giving it the opportunity to detect and bind the $\alpha_\beta_3$-integrin receptor expressed in proliferating tumor cells in the tumor matrix. These additional molecular targets are not available to the nanoparticles.

![Figure 5. Normalized fluorescence of ex vivo tumor and muscle tissues 24 h after injection of near-infrared fluorescent imaging agents. $\alpha_\beta_3$-integrin-targeted imaging agents showed significantly higher tumor specificity relative to nontargeted near-infrared fluorescent nanoparticles ($p < 0.01$). Data for cyp–PFC-tNPs (2 $\times 10^{10}$ particles/ml; n = 3 tumors) and cyp–cRGDFK (n = 3) and for cyp–PFC-NPs (2 $\times 10^{10}$ particles/ml; n = 2 tumors). Error bars indicate standard deviation.](image-url)
Thus, the targeted small molecular probe gave optimal contrast much earlier than the nanoparticles due to higher tissue permeability and faster blood and tissue clearance. The nanoparticles remained within the vasculature for prolonged periods, allowing thorough interrogation of α3β1 integrin receptor expression within the blood vessels (10,24). However, the long circulation time of the nanoparticles has the disadvantage of higher background signal at early imaging time points after injection of the optical imaging agent, which is not apparent with less sensitive techniques, such as MRI (12,13). In certain situations, long-circulating imaging agents could be an asset in molecular imaging of diseases. Some target receptors are known to internalize in cells after binding of their ligands and subsequently returned to the cell surface to bind more ligands. In this case, the availability of the imaging agent in circulating blood would allow the receptor to bind more agents, thereby amplifying the local imaging signal through receptor-mediated endocytosis. In addition, long retention time of imaging agents in tumors could be advantageous. These situations may include clinical settings when a longer time is necessary between administration and noninvasive imaging and intraoperative image guidance for tumor resection or biopsy.

Conclusion

We demonstrated the complementary aspects of using small molecular probes and nanoparticles in molecular imaging of tumors. The imaging contrast generated by these agents depends on the tumor model used. The relatively larger tumor size and smaller, localized angiogenic vessels in the subcutaneous than in the intradermal tumor model favor the use of small molecular probes for tumor imaging and diagnosis. The small-molecule contrast agent diffuses easily from the tumor vasculature and can target α3β1-integrins expressed by tumor cells and endothelial cells, providing higher overall tumor detection sensitivity. However, the imaging contrast by the vascular-constrained NIR fluorescent nanoparticles more reliably reflected the angiogenesis-related luminal expression of α3β1, and thus aggressiveness of the tumors. On the contrary, the fluorescent nanoparticles provided higher imaging contrast than the small molecular probes when we used the intradermal tumor model. The thin and well-vascularized model with high vascular density relative to the tumor size provided more binding sites for the nanoparticles at early time points, but the rapid extravasation of the small molecular probe increased background fluorescence, favoring the use of nanoparticles in the intradermal tumor model than the small molecular probes. Taken together, both molecular imaging strategies are useful for reporting α3β1-integrin expressed by tumor cells and tumor-induced endothelial cells.

Future perspective

Numerous new imaging agents have been described in recent years and many more are under development for molecular imaging applications using disparate reporting strategies, such as small molecules and nanoparticles. As the field of molecular imaging advances, there is a need to provide guidance regarding the use of these diverse imaging agents. Here, we demonstrated the utility of two molecular imaging agents that target the same cell-surface receptor, but report different information based on the relative differences of target accessibility. We envision the combination of these small molecular reporters and nanoparticles to access tumor aggressiveness and viability. In the case of the α3β1-integrin receptor, nanoparticles could first be used to delineate tumor-induced angiogenesis and small molecular probes would report the proliferative potential of the tumor tissue. In developing new molecular probes for tumor imaging; the choice of animal model could influence the outcome. It is important to use different animal models to assess the robustness of imaging agents in identifying and reporting the molecular target with high tumor-to-surrounding tissue contrast.

Executive summary

- There is potential synergy between small-molecular-probe and fluorescent-nanoparticle approaches in cancer imaging.
- The vascular constraint of nanoparticle contrast agents yields selectivity for imaging tumor-induced angiogenesis relative to highly diffusible small molecular probes.
- The diffusivity of small molecules is important to interrogate integrin expression on the tumor tissue directly.
- Therefore, both approaches could serve synergistically to provide a comprehensive analysis of integrin expression in tumor tissue and the neovascular system.
- An intradermal tumor model with high-density tumor-induced angiogenesis favors high contrast using fluorescent nanoparticles, but subcutaneous tumors with peripheral blood vessels require rapid diffusion to the target tumor tissue, thereby favoring small molecular probes. The thin ear tissue allowed the resolution of small blood vessels from nonvascular tissues by contrast agent fluorescence.
Beyond imaging application, a combination of both delivery methods could provide a comprehensive strategy to treat tumor tissue and inhibit angiogenesis.

Acknowledgements
The authors would like to thank Gail Sadow for excellent technical assistance and Dipanjan Pan for the cartoon of the nanoparticle in Figure 1.

Financial & competing interests disclosure
This work was supported in part by NIH grants: U54 CA136398, R01 CA109754, RO1 EB008111 and U54 CA119342. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Bibliography
Papers of special note have been highlighted as:
* of interest
** of considerable interest

5. Review of integrin-targeting peptide technology for molecular imaging.

**Demonstration of the heterogeneous nature of angiogenesis-related integrin expression in a preclinical cancer xenograft model as detected using perfluorocarbon-based targeted nanoparticles similar to those described in the current report.**

Review and discussion of practical biological aspects of nanoparticles applied to biological imaging.


